Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (26935)	10/31/2005 7:44:29 PM
From: micdundee2	Respond to of 48461

thanks WJ

To: Bucky Katt who wrote (26935)	11/1/2005 8:29:13 AM
From: George Burdell	Respond to of 48461

New rat list And there was much rejoicing

To: Bucky Katt who wrote (26935)	11/1/2005 9:44:12 AM
From: pjross	Respond to of 48461

New rat list, some new and some old names>>>>>>>>> these are low priced> What?! And JMAR is not on that list?! What's up wid dat. .....just kiddin'

To: Bucky Katt who wrote (26935)	11/7/2005 9:58:55 AM
From: George Burdell	Read Replies (1) \| Respond to of 48461

QSC taking the early lead on your recent rat list finance.yahoo.com

To: Bucky Katt who wrote (26935)	11/10/2005 4:24:55 PM
From: xcr600	Read Replies (1) \| Respond to of 48461

Nibbled on a little AAC today..

To: Bucky Katt who wrote (26935)	11/30/2005 9:27:05 AM
From: George Burdell	Respond to of 48461

ISV off your Halloween scan active in premarket on this news InSite Vision Incorporated (AMEX:ISV - News) today announced positive top-line results from a pivotal phase 3 clinical trial of AzaSite(TM), a sterile, topical ophthalmic anti-infective solution containing 1.0% azithromycin formulated in DuraSite® (the Company's patented drug delivery system). In an international, controlled clinical trial, subjects with bacterial conjunctivitis (pink-eye) were treated with either AzaSite dosed twice a day for the first 2 days, followed by once a day for the next 3 days or 0.3% tobramycin dosed four times a day for 5 days. AzaSite demonstrated a clinical resolution rate of 80% as compared to 78% for tobramycin. This result shows that the clinical resolution rate of AzaSite is equivalent to tobramycin, the primary efficacy endpoint of the study, according to statistical criteria which were previously agreed to by the FDA. The bacterial eradication rate was also equivalent for both groups. biz.yahoo.com